Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Obeticholic acid (OCA) and fibrates therapy results in biochemical improvement in placebo-controlled trials in patients with primary biliary cholangitis and insufficient response to ursodeoxycholic acid. There is scarce information outside of clinical trials. Therefore, we have assessed the effectiveness and adverse events of these treatments. METHODS: Data from patients included in the ColHai registry treated with OCA, fibrates, or both were recorded during a year, as well as adverse events and treatment discontinuation. RESULTS: Eighty-six patients were treated with OCA, 250 with fibrates (81% bezafibrate; 19% fenofibrate), and 15 with OCA plus fibrates. OCA group had baseline significantly higher alkaline phosphatase (ALP) (P = 0.01) and lower platelets (P = 0.03) than fibrates. Both treatments significantly decreased ALP, gamma-glutamyl transferase (GGT), and transaminases and improved Globe score. Albumin and immunoglobulin type M improved in the fibrates group. ALP decrease was higher under fibrates, whereas alanine aminotransferase decline was higher under OCA. Although baseline transaminases and GGT were higher in patients with OCA plus fibrates, significant ALP, GGT, alanine aminotransferase, and Globe score improvement were observed during triple therapy. Adverse events were reported in 14.7% of patients (21.3% OCA; 17.6% fenofibrate; 10.7% bezafibrate), mainly pruritus (10.1% with OCA). Discontinuation was more frequent in fenofibrate treatment mainly because of intolerance or adverse events. DISCUSSION: Second-line therapy with OCA or fibrates improves hepatic biochemistry and the GLOBE score in primary biliary cholangitis patients with suboptimal response to ursodeoxycholic acid. Simultaneous treatment with OCA and fibrates improved ALP as well.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131 · cited 2×
“OCA in addition to UDCA (6,8) or in monotherapy (7,8) results in biochemical improvement in liver parameters such as alkaline phosphatase (ALP) and bilirubin, which are associated with the prognosis of the disease, and has demonstrated efficacy in phase II (6,7) and III placebo-controlled (8) trials.”
BackgroundResultSelf-citationParés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756 · cited 8×
“Response toUDCAafter 1 year: Barcelona (1), Paris I (3) and Paris II (4) criteria, and the GLOBE-PBC (19) and UK-PBC (20) prognostic scores were calculated in the cases with available data.”
MethodSelf-citationPellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025529g · Cited by 743
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646
Hirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Parés, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.12.005 · Cited by 576 · cited 1×
“OCA in addition to UDCA (6,8) or in monotherapy (7,8) results in biochemical improvement in liver parameters such as alkaline phosphatase (ALP) and bilirubin, which are associated with the prognosis of the disease, and has demonstrated efficacy in phase II (6,7) and III placebo-controlled (8) trials.”
BackgroundSelf-citationLammers, W. J., Hirschfield, G. M., Corpechot, C., Nevens, F., Lindor, K. D., Janssen, H. L. A., Floreani, A., Ponsioen, C. Y., Mayo, M. J., Invernizzi, P., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.061 · Cited by 441
Self-citationKumagi, T., Guindi, M., Fischer, S. E., Arenovich, T., Abdalian, R., Coltescu, C., Heathcote, J. E., & Hirschfield, G. M. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.216 · Cited by 372
Carbone, M., Sharp, S. J., Flack, S., Paximadas, D., Spiess, K., Adgey, C., Griffiths, L., Lim, R., Trembling, P., Williamson, K., et al. (2016) · Hepatology · doi:10.1002/hep.28017 · Cited by 354 · cited 6×
“Response toUDCAafter 1 year: Barcelona (1), Paris I (3) and Paris II (4) criteria, and the GLOBE-PBC (19) and UK-PBC (20) prognostic scores were calculated in the cases with available data.”
BackgroundMethodInfluentialA randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis
Kowdley, K. V., Luketic, V., Chapman, R., Hirschfield, G. M., Poupon, R., Schramm, C., Vincent, C., Rust, C., Parés, A., Mason, A., et al. (2018) · Hepatology · doi:10.1002/hep.29569 · Cited by 281
Self-citationTrauner, M., Nevens, F., Shiffman, M. L., Drenth, J. P. H., Bowlus, C. L., Vargas, V., Andreone, P., Hirschfield, G. M., Pencek, R., Malecha, E. S., et al. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30094-9 · Cited by 180
Self-citation
Cited by
Primary biliary cholangitis: Epidemiology, prognosis, and treatment
Trivella, J., John, B. V., & Levy, C. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000179 · Cited by 159
Ampuero, J., Lucena, A., Berenguer, M., Hernández-Guerra, M., Molina, E., Gómez-Camarero, J., Valdivia, C., Gómez, E., Casado, M., Álvarez-Navascuez, C., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000826 · Cited by 17
Self-citationAdvancing care in primary biliary cholangitis: emerging insights and novel therapies
Vögelin, M., & Kremer, A. E. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2516622 · Cited by 5
“Early phase 2 studies from the EU and the USA also indicate a potential additive effect of combining OCA and fibrates, with significant biochemical improvement in these problematic cases [75,76].”
Metadata
- Authors
- Reig, A., Álvarez-Navascués, C., Vergara, M., Gómez-Domínguez, E., Gallego-Moya, A., Pérez-Medrano, I. M., Fábrega, E., Hernández-Guerra, M., Berenguer, M., Estevez, P., Arencibia, A., Morillas, R. M., Horta, D., Albillos, A., Casado, M., De la Cruz, G., Fernandez-Bonilla, E., Molina, E., Hijona, L., Diago, M., Fernández-Rodriguez, C. M., González-Santiago, J. M., Sala, M., Gómez-Camarero, J., Romero-Gomez, M., Suárez, F., Vargas, V., Ferre-Aracil, C., Andrade, R. J., Chahri, N., & Parés, A.
- Venue
- American Journal of Gastroenterology
- Published
- 2021-06-23
- Volume
- 116
- Issue
- 11
- Pages
- 2250-2257
- ISSN
- 0002-9270 (ISSN-L)
- 1572-0241
- OpenAlex
- W3174888168
- Cited by
- 35
- References
- 13
- FWCI
- 2.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study. https://app.cochat.ai/papers/10.14309/ajg.0000000000001343
- The paper
- Reig, A., Álvarez-Navascués, C., Vergara, M., Gómez-Domínguez, E., Gallego-Moya, A., Pérez-Medrano, I. M., Fábrega, E., Hernández-Guerra, M., Berenguer, M., Estevez, P., Arencibia, A., Morillas, R. M., Horta, D., Albillos, A., Casado, M., De la Cruz, G., Fernandez-Bonilla, E., Molina, E., Hijona, L., . . . Parés, A. (2021). Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study. American Journal of Gastroenterology. https://doi.org/10.14309/ajg.0000000000001343
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.